Arbutus Biopharma Corp (ABUS)
3.73
+0.08
(+2.19%)
USD |
NASDAQ |
Nov 14, 12:34
Arbutus Biopharma Cash from Financing (Quarterly): 1.775M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.775M |
| June 30, 2024 | 24.37M |
| March 31, 2024 | 24.43M |
| December 31, 2023 | 3.807M |
| September 30, 2023 | 1.681M |
| June 30, 2023 | 4.742M |
| March 31, 2023 | 20.42M |
| December 31, 2022 | 11.08M |
| September 30, 2022 | 9.132M |
| June 30, 2022 | 0.113M |
| March 31, 2022 | 11.48M |
| December 31, 2021 | 59.12M |
| September 30, 2021 | 46.95M |
| June 30, 2021 | 4.289M |
| March 31, 2021 | 26.87M |
| December 31, 2020 | 20.21M |
| September 30, 2020 | 49.10M |
| June 30, 2020 | 4.959M |
| March 31, 2020 | 12.48M |
| December 31, 2019 | 13.89M |
| September 30, 2019 | 18.55M |
| June 30, 2019 | 2.479M |
| March 31, 2019 | 2.536M |
| December 31, 2018 | 0.109M |
| September 30, 2018 | 0.435M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.735M |
| March 31, 2018 | 54.37M |
| December 31, 2017 | 48.90M |
| September 30, 2017 | 0.061M |
| June 30, 2017 | 0.004M |
| March 31, 2017 | 0.354M |
| December 31, 2016 | 12.00M |
| September 30, 2016 | 0.076M |
| June 30, 2016 | 0.446M |
| March 31, 2016 | 0.115M |
| December 31, 2015 | -0.025M |
| September 30, 2015 | 0.115M |
| June 30, 2015 | 0.96M |
| March 31, 2015 | 142.82M |
| December 31, 2014 | 0.469M |
| September 30, 2014 | 0.684M |
| June 30, 2014 | 0.234M |
| March 31, 2014 | 59.29M |
| December 31, 2013 | 32.43M |
| September 30, 2013 | 0.076M |
| June 30, 2013 | 0.068M |
| March 31, 2013 | 0.138M |
| December 31, 2012 | 0.6388M |
| September 30, 2012 | 0.1298M |
| June 30, 2012 | -0.0731M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.113M
Minimum
Jun 2022
59.12M
Maximum
Dec 2021
17.55M
Average
11.98M
Median
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| Amicus Therapeutics Inc | 18.19M |
| Ionis Pharmaceuticals Inc | 496.05M |
| GlycoMimetics Inc | 0.0005M |
| FibroGen Inc | 0.032M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.74M |
| Cash from Investing (Quarterly) | -11.99M |
| Free Cash Flow | -71.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1097 |
| Free Cash Flow to Equity (Quarterly) | -20.74M |
| Free Cash Flow Yield | -10.69% |